| Name | Support | Language | Availability | Edition date | Price | ||
|---|---|---|---|---|---|---|---|
|
PDF |
English |
Active |
1/1/2020 |
€46.00 |
|
||
|
PDF |
English |
Active |
1/1/2020 |
€53.00 |
|
||
Details
1.1 ,This guide provides information to determine the appropriate testing for biocompatibility of medical device packaging materials that have the potential to contact the patient directly or indirectly.
1.2 ,This guide does not apply to secondary or tertiary packaging materials.
1.3 ,This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.
1.4 ,This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
Significance and Use:
5.1 ,The compatibility of packaging materials with a medical device is a requirement of many regulatory bodies. Since most medical devices are used or implanted in, around, or on the human body, the benefits of these devices must outweigh the risks. Therefore, the packaging materials that come in contact with the medical device must also be evaluated and determined to be safe for use with the human body in that they have no negative impact on the physical, chemical, or biological properties of the device. This evaluation may include both a study of relevant experience with, and actual testing of, packaging materials. Such an evaluation may result in the conclusion that no testing is needed if the material has a demonstrable history of safe use in the specific role that is the same as that of the package under design.
5.2 ,The medical device manufacturer determines the need for appropriate testing, with consideration of the device/package interactions, if any. When screening information is needed regarding the biocompatibility of the packaging, cytotoxicity testing from the supplier is typically performed.
Additional Info
| Author | American Society for Testing and Materials (ASTM International) |
|---|---|
| Committee | F02.15 - Committee F02 on Primary Barrier Packaging |
| Published by | ASTM |
| Document type | Standard |
| Theme | ,Other standards related to pharmaceutics,Packaging and distibution of goods in general |
| ICS | 11.120.99 : Other standards related to pharmaceutics
55.020 : Packaging and distribution of goods in general |
| Number of pages | 3 |
| Replace | ASTM F2475-11 |
| Set | ASTM Volume 15.10 - Multi-User - Single-Site Online |
| Document history | , |
| Keyword | F2475 |
